Allergan plc (NYSE:AGN) plans to divest its women's health and anti-infectives businesses, CEO Brent Saunders said Wednesday at an investor conference in New York. The decision follows a strategic review the company announced in March.
Saunders said the company will now focus on gastrointestinal and CNS diseases, medical aesthetics and eye care.
Last year, Allergan's women's health products brought in $1 billion in revenue and its anti-infectives generated $257 million, together accounting for about 20% of the company's $5.8 billion 2017 revenue.
Allergan added $0.49 to $151.52 on Wednesday.